CN111643058A - 比率型近红外ii区荧光探针、其构建方法及应用 - Google Patents
比率型近红外ii区荧光探针、其构建方法及应用 Download PDFInfo
- Publication number
- CN111643058A CN111643058A CN202010534705.7A CN202010534705A CN111643058A CN 111643058 A CN111643058 A CN 111643058A CN 202010534705 A CN202010534705 A CN 202010534705A CN 111643058 A CN111643058 A CN 111643058A
- Authority
- CN
- China
- Prior art keywords
- infrared
- hairpin structure
- fluorescent probe
- dna hairpin
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 35
- 238000010276 construction Methods 0.000 title claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 45
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 45
- 239000002096 quantum dot Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 108091070501 miRNA Proteins 0.000 claims abstract description 12
- 239000002679 microRNA Substances 0.000 claims abstract description 12
- 230000003321 amplification Effects 0.000 claims abstract description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 210000000170 cell membrane Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 229940009456 adriamycin Drugs 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 238000012412 chemical coupling Methods 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 229910002688 Ag2Te Inorganic materials 0.000 claims description 2
- 229910005542 GaSb Inorganic materials 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- WPYVAWXEWQSOGY-UHFFFAOYSA-N indium antimonide Chemical compound [Sb]#[In] WPYVAWXEWQSOGY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 abstract description 7
- 238000011065 in-situ storage Methods 0.000 abstract description 6
- 238000011156 evaluation Methods 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000002243 precursor Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000011503 in vivo imaging Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108700019961 Neoplasm Genes Proteins 0.000 description 3
- 102000048850 Neoplasm Genes Human genes 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- XCAUINMIESBTBL-UHFFFAOYSA-N lead(ii) sulfide Chemical compound [Pb]=S XCAUINMIESBTBL-UHFFFAOYSA-N 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910000004 White lead Inorganic materials 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108091044988 miR-125a stem-loop Proteins 0.000 description 1
- 108091030938 miR-424 stem-loop Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000005005 sentinel lymph node Anatomy 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0091—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for mammography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010534705.7A CN111643058A (zh) | 2020-06-12 | 2020-06-12 | 比率型近红外ii区荧光探针、其构建方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010534705.7A CN111643058A (zh) | 2020-06-12 | 2020-06-12 | 比率型近红外ii区荧光探针、其构建方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111643058A true CN111643058A (zh) | 2020-09-11 |
Family
ID=72347598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010534705.7A Pending CN111643058A (zh) | 2020-06-12 | 2020-06-12 | 比率型近红外ii区荧光探针、其构建方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111643058A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113981004A (zh) * | 2021-11-01 | 2022-01-28 | 中国科学院苏州纳米技术与纳米仿生研究所 | 细胞膜电位检测的遗传编码纳米探针及其制备方法与应用 |
CN114940669A (zh) * | 2022-05-30 | 2022-08-26 | 中国科学院苏州纳米技术与纳米仿生研究所 | 单组分nir-ii区比率荧光纳米探针、制备方法及产品 |
CN115207259A (zh) * | 2022-09-14 | 2022-10-18 | 上海南麟电子股份有限公司 | 基于量子点的单光子源及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198447A (zh) * | 2014-07-24 | 2014-12-10 | 江苏大学 | 一种双发射比率型量子点荧光探针及其制备方法和应用 |
CN108309995A (zh) * | 2018-01-16 | 2018-07-24 | 华中师范大学 | 一种基于化学信号诱导的刺激-响应磁性纳米粒子的药物释放体系 |
CN108624620A (zh) * | 2018-04-02 | 2018-10-09 | 湖南大学 | DNA纳米四分体实现对核酸高效输送及miRNA的超灵敏检测方法 |
CN110746963A (zh) * | 2019-09-18 | 2020-02-04 | 广西师范大学 | 近红外发光的生物质量子点和细胞内mRNA比率荧光成像的纳米探针及其制备方法和应用 |
CN110819716A (zh) * | 2019-11-28 | 2020-02-21 | 中国科学院苏州纳米技术与纳米仿生研究所 | 激活型近红外二区分子信标探针组合物及其应用 |
-
2020
- 2020-06-12 CN CN202010534705.7A patent/CN111643058A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198447A (zh) * | 2014-07-24 | 2014-12-10 | 江苏大学 | 一种双发射比率型量子点荧光探针及其制备方法和应用 |
CN108309995A (zh) * | 2018-01-16 | 2018-07-24 | 华中师范大学 | 一种基于化学信号诱导的刺激-响应磁性纳米粒子的药物释放体系 |
CN108624620A (zh) * | 2018-04-02 | 2018-10-09 | 湖南大学 | DNA纳米四分体实现对核酸高效输送及miRNA的超灵敏检测方法 |
CN110746963A (zh) * | 2019-09-18 | 2020-02-04 | 广西师范大学 | 近红外发光的生物质量子点和细胞内mRNA比率荧光成像的纳米探针及其制备方法和应用 |
CN110819716A (zh) * | 2019-11-28 | 2020-02-21 | 中国科学院苏州纳米技术与纳米仿生研究所 | 激活型近红外二区分子信标探针组合物及其应用 |
Non-Patent Citations (1)
Title |
---|
YU-LAN HU 等: "Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy", 《JOURNAL OF CONTROLLED RELEASE》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113981004A (zh) * | 2021-11-01 | 2022-01-28 | 中国科学院苏州纳米技术与纳米仿生研究所 | 细胞膜电位检测的遗传编码纳米探针及其制备方法与应用 |
CN113981004B (zh) * | 2021-11-01 | 2024-02-09 | 中国科学院苏州纳米技术与纳米仿生研究所 | 细胞膜电位检测的遗传编码纳米探针及其制备方法与应用 |
CN114940669A (zh) * | 2022-05-30 | 2022-08-26 | 中国科学院苏州纳米技术与纳米仿生研究所 | 单组分nir-ii区比率荧光纳米探针、制备方法及产品 |
CN114940669B (zh) * | 2022-05-30 | 2024-04-12 | 中国科学院苏州纳米技术与纳米仿生研究所 | 单组分nir-ii区比率荧光纳米探针、制备方法及产品 |
CN115207259A (zh) * | 2022-09-14 | 2022-10-18 | 上海南麟电子股份有限公司 | 基于量子点的单光子源及其制备方法 |
CN115207259B (zh) * | 2022-09-14 | 2022-11-29 | 上海南麟电子股份有限公司 | 基于量子点的单光子源及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111643058A (zh) | 比率型近红外ii区荧光探针、其构建方法及应用 | |
Pu et al. | Recent advances of semiconducting polymer nanoparticles in in vivo molecular imaging | |
Massey et al. | Mind your P's and Q's: the coming of age of semiconducting polymer dots and semiconductor quantum dots in biological applications | |
Sharifi et al. | Development of point-of-care nanobiosensors for breast cancers diagnosis | |
Zhong et al. | Synthesizing anode electrochemiluminescent self-catalyzed carbon dots-based nanocomposites and its application in sensitive ECL biosensor for microRNA detection | |
Vandghanooni et al. | Recent advances in aptamer-based nanosystems and microfluidics devices for the detection of ovarian cancer biomarkers | |
Li et al. | Nanomaterial based analytical methods for breast cancer biomarker detection | |
Khazaei et al. | Nanosensors and their applications in early diagnosis of cancer | |
Zhang et al. | Cell membrane coated smart two-dimensional supraparticle for in vivo homotypic cancer targeting and enhanced combinational theranostics | |
Men et al. | Biomimetic semiconducting polymer dots for highly specific NIR-II fluorescence imaging of glioma | |
Rahim et al. | Bioorthogonal chemistries for nanomaterial conjugation and targeting | |
Peng et al. | Silicon nanostructures for cancer diagnosis and therapy | |
Yu et al. | Noninvasive and highly multiplexed five-color tumor imaging of multicore near-infrared resonant surface-enhanced Raman nanoparticles in vivo | |
Yang et al. | A two-photon metal-organic framework nanoprobe with catalytic hairpin assembly for amplified MicroRNA imaging in living cells and tissues | |
Borghei et al. | A novel dual-mode and label-free aptasensor based methodology for breast cancer tissue marker targeting | |
Karunakaran et al. | Elucidating Raman image-guided differential recognition of clinically confirmed grades of cervical exfoliated cells by dual biomarker-appended SERS-tag | |
Grumezescu | Design of nanostructures for theranostics applications | |
He et al. | Ultrasensitive fluorescence detection of microRNA through DNA-induced assembly of carbon dots on gold nanoparticles with no signal amplification strategy | |
Sobhanan et al. | Multimodal CTC detection using stem cell antigen-specific immunosilica particles and immunofluorescent quantum dots | |
Li et al. | Designing intelligent nanomaterials to achieve highly sensitive diagnoses and multimodality therapy of bladder cancer | |
Hallaj et al. | Induced ultrasensitive electrochemical biosensor for target MDA-MB-231 cell cytoplasmic protein detection based on RNA-cleavage DNAzyme catalytic reaction | |
Sun et al. | In situ detection of exosomal RNAs for cancer diagnosis | |
KR101692052B1 (ko) | 표면 증강 라만 산란 방법(sers)을 이용하여 순환 종양세포 및 순환 종양 줄기유사세포를 검출하는 방법 및 이를 이용한 시스템 | |
Shu et al. | Catalytic probes based on aggregation-induced emission-active Au nanoclusters for visualizing MicroRNA in living cells and in vivo | |
Zhang et al. | Controllable Assembly of a Quantum Dot-Based Aptasensor Guided by CRISPR/Cas12a for Direct Measurement of Circulating Tumor Cells in Human Blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201127 Address after: Room 404, Southeast Institute (1), science and Technology Park, Southeast University, 399 Linquan street, Suzhou Industrial Park, Jiangsu Province, 215000 Applicant after: SUZHOU NIR OPTICS TECHNOLOGY Co.,Ltd. Address before: 215123, Suzhou, Jiangsu province Suzhou Industrial Park alone villa lake high Parish, if the waterway 398 Applicant before: SUZHOU INSTITUTE OF NANO-TECH AND NANO-BIONICS (SINANO), CHINESE ACADEMY OF SCIENCES |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200911 |